NurExone Biologic Inc

TSXV:NRX Canada Healthcare — Biotechnology

NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. It offers ExoPTEN, for treatment of acute spinal cord inj…

nurexone.com

Click to toggle · Cmd+Click for exclusive

News 2026-05-19

Open PDF

NurExone Receives Notice of Patent Grant in South Korea Covering ExoPTEN Technology

News release - English.pdf

News 2026-05-14

Open PDF

NurExone Advances to Stage 2 of EU-Backed EIT Health Catapult Programme 2026

News release - English.pdf

News 2026-04-27

Open PDF

NurExone Biologic Inc. Granted Australian Patent for Stem Cell-Derived Exosome Production

News release - English.pdf

Results 2026-04-16

Open PDF

NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update

News release - English.pdf

Results 2026-04-16

Open PDF

Annual MD&A - English.pdf

Results 2026-04-16

Open PDF

Audited annual financial statements – English.pdf

Transactions 2026-04-07 M&A

Open PDF

NurExone Biologic's U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization

News release - English.pdf

News 2026-04-01

Open PDF

NurExone Receives First Place in Healthcare at BOLD Awards VII and Engages Investor Brand Network to Support Awareness Strategy

News release - English.pdf

Transactions 2026-03-26 M&A

Open PDF

NurExone Strengthens U.S. Manufacturing Strategy Through Exo-Top Sublicense Agreement

News release - English.pdf

News 2026-03-20

Report of exempt distribution (45-106F1).pdf

Transactions 2026-03-19 Financing

Open PDF

NurExone Biologic Inc. Closes Non-Brokered Private Placement for Aggregate Gross Proceeds of C$880,750.96

Material change report - English.pdf

Transactions 2026-03-11 Financing

Open PDF

NurExone Announces Corporate Updates: Consulting Agreement with Former Bayer Principal Scientist, BOLD Awards Healthcare Finalist Status, and Private Placement Closing

News release - English.pdf

News 2026-02-27

Open PDF

NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update

News release - English.pdf

News 2026-02-10

Open PDF

NurExone Biologic Advances Manufacturing and Regulatory Roadmap with Independent Batch Consistency Results for Exosome Production

News release - English.pdf

News 2025-12-19

Open PDF

NurExone Reports Anti-Inflammatory Activity of Its Exosomes in Lab Analysis